• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Human cytomegalovirus resistance to antiviral drugs.人巨细胞病毒对抗病毒药物的耐药性。
Antimicrob Agents Chemother. 2005 Mar;49(3):873-83. doi: 10.1128/AAC.49.3.873-883.2005.
2
Cytomegalovirus (CMV) resistance to antivirals.巨细胞病毒（CMV）对抗病毒药物的耐药性。
Am J Transplant. 2001 Nov;1(4):307-12.
3
Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.人巨细胞病毒对抗病毒药物的耐药性：诊断、监测及临床影响。
J Antimicrob Chemother. 2003 Sep;52(3):324-30. doi: 10.1093/jac/dkg354. Epub 2003 Jul 29.
4
Cytomegalovirus resistance testing: pitfalls and problems for the clinician.巨细胞病毒耐药性检测：临床医生的陷阱和问题。
Clin Infect Dis. 2010 Mar 1;50(5):733-6. doi: 10.1086/650463.
5
Differential resistance to antiviral drugs in an immunocompromised patient with cytomegalovirus encephalitis.一名患有巨细胞病毒性脑炎的免疫功能低下患者对抗病毒药物的耐药性差异
J Clin Virol. 2010 Nov;49(3):223-4. doi: 10.1016/j.jcv.2010.07.023. Epub 2010 Aug 30.
6
Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.造血干细胞移植中人类巨细胞病毒抗病毒药物耐药性：现状。
Rev Med Virol. 2016 May;26(3):161-82. doi: 10.1002/rmv.1873. Epub 2016 Mar 14.
7
Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection.青蒿琥酯在控制缬更昔洛韦耐药的巨细胞病毒感染方面无效。
Clin Infect Dis. 2011 Jan 15;52(2):279. doi: 10.1093/cid/ciq050.
8
Drug resistance in cytomegalovirus: current knowledge and implications for patient management.
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12 Suppl 1:S1-22.
9
Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management.巨细胞病毒抗病毒药物耐药性：预防、检测与管理的未来前景
Future Microbiol. 2015;10(10):1545-8. doi: 10.2217/fmb.15.82. Epub 2015 Oct 6.
10
Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.心脏移植受者中耐更昔洛韦巨细胞病毒感染的病毒监测及成功治疗
Transpl Infect Dis. 2008 Apr;10(2):123-8. doi: 10.1111/j.1399-3062.2007.00243.x. Epub 2007 Jul 1.

引用本文的文献

1
A New Next-Generation Sequencing Approach in Human Cytomegalovirus for the Identification of Antiviral Resistance Mutations and Genotypic Classification.一种用于鉴定人巨细胞病毒抗病毒耐药突变和基因分型的新型下一代测序方法
J Med Virol. 2025 Aug;97(8):e70523. doi: 10.1002/jmv.70523.
2
Digital PCR-Based Genotyping: A Precision Approach to HCMV Drug Resistance.基于数字PCR的基因分型：一种检测人巨细胞病毒耐药性的精准方法
Methods Mol Biol. 2025;2943:19-29. doi: 10.1007/978-1-0716-4642-7_2.
3
Human Cytomegalovirus UL78 is a Nuclear-Localized GPCR Necessary for Efficient Reactivation from Latent Infection in CD34 Hematopoietic Progenitor Cells.人巨细胞病毒UL78是一种定位于细胞核的GPCR，对于CD34造血祖细胞潜伏感染的有效再激活是必需的。
bioRxiv. 2025 Jun 2:2025.06.02.657350. doi: 10.1101/2025.06.02.657350.
4
Infections of the Corneal Endothelium.角膜内皮感染
Microorganisms. 2025 Mar 28;13(4):778. doi: 10.3390/microorganisms13040778.
5
The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.《实体器官移植中巨细胞病毒管理的第四届国际共识指南》
Transplantation. 2025 Jul 1;109(7):1066-1110. doi: 10.1097/TP.0000000000005374. Epub 2025 Apr 9.
6
Efficacy of antimicrobials in preventing resistance in solid organ transplant recipients: A systematic review of clinical trials.抗菌药物在预防实体器官移植受者耐药方面的疗效：一项临床试验的系统评价
World J Transplant. 2025 Mar 18;15(1):98003. doi: 10.5500/wjt.v15.i1.98003.
7
Third intracellular loop of HCMV US28 is necessary for signaling and viral reactivation.人巨细胞病毒US28的第三个细胞内环对于信号传导和病毒再激活是必需的。
J Virol. 2025 Jan 31;99(1):e0180124. doi: 10.1128/jvi.01801-24. Epub 2024 Dec 10.
8
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.目前和新兴的抗病毒药物在儿科移植受者巨细胞病毒预防和治疗中的应用。
J Pediatric Infect Dis Soc. 2024 Feb 28;13(Supplement_1):S14-S21. doi: 10.1093/jpids/piad059.
9
A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B.一种针对人巨细胞病毒糖蛋白 B 高度保守表位的完全人源中和性单克隆抗体。
PLoS One. 2023 May 16;18(5):e0285672. doi: 10.1371/journal.pone.0285672. eCollection 2023.
10
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients.更昔洛韦群体药代动力学和药效学分析在优化肾移植受者巨细胞病毒感染的 preemptive 治疗中的应用。
Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0166522. doi: 10.1128/aac.01665-22. Epub 2023 Feb 23.

本文引用的文献

1
Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.巨细胞病毒抗病毒耐药性与治疗诱导的 UL97（蛋白激酶）和 UL54（DNA 聚合酶）突变相关。
J Med Virol. 2004 Sep;74(1):85-93. doi: 10.1002/jmv.20150.
2
Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.西多福韦醚脂质酯前药对实验性人巨细胞病毒感染的口服活性
J Infect Dis. 2004 Aug 1;190(3):499-503. doi: 10.1086/421912. Epub 2004 Jul 1.
3
Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.人巨细胞病毒 UL27 基因中赋予对马立巴韦耐药性的突变。
J Virol. 2004 Jul;78(13):7124-30. doi: 10.1128/JVI.78.13.7124-7130.2004.
4
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.在一项针对实体器官移植受者的前瞻性多中心研究中，缬更昔洛韦预防治疗后未出现巨细胞病毒耐药突变。
J Infect Dis. 2004 May 1;189(9):1615-8. doi: 10.1086/382753. Epub 2004 Apr 13.
5
Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus.核糖吡喃糖苷苯并咪唑GW275175X抗人巨细胞病毒的作用机制。
Antimicrob Agents Chemother. 2004 May;48(5):1647-51. doi: 10.1128/AAC.48.5.1647-1651.2004.
6
The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host.人巨细胞病毒的UL97蛋白激酶及其他疱疹病毒中的同源物：对病毒和宿主的影响
Biochim Biophys Acta. 2004 Mar 11;1697(1-2):169-80. doi: 10.1016/j.bbapap.2003.11.022.
7
Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.一名供体阳性/受体阴性肺移植患者出现人巨细胞病毒双重耐药，其CD4介导的特异性免疫反应受损。
J Antimicrob Chemother. 2004 Mar;53(3):536-9. doi: 10.1093/jac/dkh065. Epub 2004 Jan 22.
8
In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients.
J Infect Dis. 2003 Dec 1;188(11):1639-47. doi: 10.1086/379376. Epub 2003 Nov 14.
9
Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.人巨细胞病毒对苯并咪唑L-核糖核苷马里巴韦的耐药性定位到UL27。
J Virol. 2003 Nov;77(21):11499-506. doi: 10.1128/jvi.77.21.11499-11506.2003.
10
The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44.人类巨细胞病毒的蛋白激酶pUL97与DNA聚合酶持续合成因子pUL44相互作用并使其磷酸化。
Virology. 2003 Jun 20;311(1):60-71. doi: 10.1016/s0042-6822(03)00147-8.

Human cytomegalovirus resistance to antiviral drugs.

作者信息

Gilbert C, Boivin G

机构信息

Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec, Université Laval, Sainte-Foy, Québec, Canada.

出版信息

Antimicrob Agents Chemother. 2005 Mar;49(3):873-83. doi: 10.1128/AAC.49.3.873-883.2005.

DOI:10.1128/AAC.49.3.873-883.2005
PMID:15728878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC549271/
Abstract
摘要